SCHEMBL17515841

SCHEMBL17515841

CON(C)C(=O)[C@H](C)NCC(=O)c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK3 P52333 1/20 0.49
BTK Q06187 1/20 0.49
KMT2A Q03164 6/20 0.44
NPC1 O15118 5/20 0.43
ALDH1A1 P00352 4/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
HPGD P15428 3/20 0.43
RAB9A P51151 3/20 0.43
AGTR1 P30556 1/20 0.43
DPP4 P27487 1/20 0.43
MEN1 O00255 4/20 0.41
MAPT P10636 2/20 0.41
CYP3A4 P08684 2/20 0.41
KDM4E B2RXH2 1/20 0.41
ALOX15 P16050 1/20 0.41
CES1 P23141 1/20 0.41
MAPK1 P28482 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
SIGMAR1 Q99720 1/20 0.40
FAAH O00519 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1274533 0.80 KMT2A (0.58) KMT2ANPC1ALDH1A1SMN1; SMN2HPGD
SCHEMBL17515839 0.78 DPP4 (0.55) KMT2ANPC1ALDH1A1SMN1; SMN2HPGD
SCHEMBL3590805 0.78 DPP4 (0.55) KMT2ANPC1ALDH1A1SMN1; SMN2HPGD
SCHEMBL15303215 0.78 SMN1; SMN2 (0.46) JAK3BTKALDH1A1SMN1; SMN2HPGD
SCHEMBL15303217 0.78 SMN1; SMN2 (0.46) JAK3BTKALDH1A1SMN1; SMN2HPGD
SCHEMBL16786071 0.77 JAK3 (0.66) JAK3BTKKMT2ANPC1ALDH1A1
SCHEMBL4102495 0.74 ALDH1A1 (0.57) KMT2ANPC1ALDH1A1SMN1; SMN2HPGD
SCHEMBL16843361 0.72 KDM4E (0.44) KMT2ANPC1ALDH1A1SMN1; SMN2HPGD
SCHEMBL18133759 0.72 KDM4E (0.44) KMT2ANPC1ALDH1A1SMN1; SMN2HPGD
SCHEMBL26199843 0.72 KMT2A (0.55) KMT2ANPC1ALDH1A1SMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9533977-B2 Oxazolidinone derivative as CETP inhibitor, its preparation method, and pharmaceutical composition comprising the same DONG-A ST CO., LTD. (KR) 2017-01-03 US disclosed
US-20160039804-A1 NOVEL OXAZOLIDINONE DERIVATIVE AS CETP INHIBITOR, ITS PREPARATION METHOD, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME DONG-A ST CO., LTD. (KR) 2016-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160039804-A1 NOVEL OXAZOLIDINONE DERIVATIVE AS CETP INHIBITOR, ITS PREPARATION METHOD, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CETP, MTTP, APOB JAK3 4704/4885BTK 1656/4885KMT2A 3192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.